source
- AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor dealAbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…